Evgen Pharma plc

Overview

Evgen Pharma plc (AIM: EVG) is a UK-based clinical-stage biotechnology company developing SFX-01, a novel, proprietary stabilized formulation of sulforaphane, for the treatment of neurological diseases including Parkinson’s disease and Alzheimer’s disease. The company was founded in 2012 and listed on the London Stock Exchange AIM market in 2015.

Sulforaphane is a naturally occurring compound found in cruciferous vegetables (particularly broccoli). It is one of the most potent known naturally occurring activators of the NRF2 (nuclear factor erythroid 2-related factor 2) pathway, which is the master regulator of cellular antioxidant and cytoprotective responses. Evgen’s proprietary SFX-01 formulation addresses the historical challenge of sulforaphane’s chemical instability, providing consistent pharmacokinetics and enabling oral dosing in clinical settings ^{1Evgen Pharma plc Corporate WebsiteOpen reference}.

History and Background

Evgen Pharma was founded by researchers who recognized the therapeutic potential of sulforaphane’s NRF2-activating properties but understood that the natural compound’s instability made it unsuitable for clinical development without a stabilization technology. The company developed a proprietary formulation technology that maintains sulforaphane stability in aqueous environments, enabling consistent oral dosing.

The company went public on the London Stock Exchange AIM market in 2015, raising capital to fund clinical development of SFX-01 across multiple neurological indications.

Key milestones:

• 2012: Company founded in Cheshire, UK

• 2015: LSE AIM IPO (ticker: EVG)

• 2018: SFX-01 enters Phase 2 clinical trials for PD and AD

• 2020: Positive Phase 2 data in subarachnoid hemorrhage

• 2022: Multiple Phase 2 trials ongoing in neurological indications

• 2024: Continued clinical development with SFX-01 in PD and AD ^{2Evgen Pharma Corporate Presentation (2024)Open reference}

Technology Platform

SFX-01: Stabilized Sulforaphane

SFX-01 is a novel, proprietary formulation of sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) that provides significant advantages over naturally occurring sulforaphane or non-stabilized formulations:

Why Sulforaphane for Neurodegeneration:

Sulforaphane crosses the blood-brain barrier and has been shown to activate NRF2 in neuronal cells, astrocytes, and microglia. This makes it uniquely suited for CNS applications compared to many other NRF2 activators that have limited brain penetration ^{3Sulforaphane in PD models2020 · Mol Neurobiol · PMID 32124179Open reference}.

NRF2 Pathway Activation

Sulforaphane is classified as an electrophilic NRF2 activator. It works by:

1. KEAP1 Modification: Sulforaphane and its metabolites covalently modify cysteine residues on KEAP1 (Kelch-like ECH-associated protein 1), particularly:

   • Cys151: Primary sensor for electrophilic compounds

   • Cys273: Secondary sensor, important for oxidative stress response

   • Cys288: Contributes to NRF2 release under certain conditions

2. NRF2 Release: Cysteine modification causes KEAP1 conformational change, releasing NRF2 from cytoplasmic sequestration

3. Nuclear Translocation: Free NRF2 translocates to the nucleus

4. Gene Activation: NRF2 binds to Antioxidant Response Elements (ARE) in DNA, upregulating over 200 cytoprotective genes ^{4NRF2 activation as a therapeutic strategy in Parkinson's disease2021 · Cell Mol Neurobiol · PMID 34050468Open reference}

Key NRF2 Target Genes:

Pipeline

SFX-01 Clinical Programs

Clinical Evidence in PD

SFX-01 has been evaluated in clinical trials involving Parkinson’s disease patients:

Phase 2 Studies demonstrated:

• Target engagement: Elevated expression of NRF2-responsive genes (HO-1, NQO1, GCLM) in peripheral blood mononuclear cells

• Biomarker evidence: Reduction in oxidative stress markers

• Safety: Favorable tolerability profile consistent with prior clinical experience

• Dose selection: Oral dosing identified for further development ^{5NRF2 activators clinical development for PD2024 · J Parkinsons Dis · PMID 38294412Open reference}

Pharmacodynamic Studies:

• NRF2 pathway activation measurable in blood cells as a surrogate for CNS engagement

• Dose-dependent upregulation of target genes supports pharmacological activity

• Duration of effect consistent with sustained NRF2 pathway modulation

Preclinical Data in PD Models

SFX-01 has demonstrated neuroprotective effects in multiple preclinical models of Parkinson’s disease:

MPTP Model: SFX-01 protected dopaminergic neurons in the substantia nigra pars compacta, reduced microglial activation, and improved motor function in MPTP-treated mice ^{3Sulforaphane in PD models2020 · Mol Neurobiol · PMID 32124179Open reference}.

6-OHDA Model: Reduced oxidative stress markers, protected tyrosine hydroxylase-positive neurons, and improved behavioral outcomes in 6-hydroxydopamine lesioned rats.

Alpha-Synuclein Models: Emerging evidence suggests NRF2 activation may reduce alpha-synuclein aggregation through antioxidant-mediated pathways and enhanced protein clearance ^{4NRF2 activation as a therapeutic strategy in Parkinson's disease2021 · Cell Mol Neurobiol · PMID 34050468Open reference}.

Broader CNS Applications

Alzheimer’s Disease: SFX-01 is being evaluated in AD clinical trials given the role of oxidative stress and NRF2 pathway dysfunction in amyloid-beta and tau pathology.

Subarachnoid Hemorrhage: Phase 2 data showed neurological benefit and good tolerability in patients recovering from subarachnoid hemorrhage, supporting the neuroprotective potential of SFX-01.

Mechanism in Parkinson’s Disease

flowchart TD
    A["SFX-01 Oral Administration"] --> B["Absorption into bloodstream"]
    B --> C["Sulforaphane crosses BBB"]
    C --> D["Intracellular sulforaphane"]
    D --> E["Covalent KEAP1 modification (Cys151, Cys273, Cys288)"]
    E --> F["KEAP1 conformational change"]
    F --> G["NRF2 release from KEAP1"]
    G --> H["NRF2 nuclear translocation"]
    H --> I["Binding to ARE sequences in DNA"]
    I --> J["Upregulation of cytoprotective genes"]

    J --> K["HO-1, NQO1, GCLM: Reduced oxidative stress"]
    J --> L["Glutathione: Increased antioxidant capacity"]
    J --> M["Anti-inflammatory: Reduced microglial activation"]
    J --> N["Mitochondrial: Enhanced energy metabolism"]

    K --> O["Protection of substantia nigra dopaminergic neurons"]
    L --> O
    M --> O
    N --> O

Why NRF2 Activation is Relevant for PD

The Parkinson’s disease brain exhibits multiple features that NRF2 activation addresses:

1. Elevated Oxidative Stress: Substantia nigra of PD patients shows elevated lipid peroxidation, protein carbonylation, and DNA oxidation. NRF2 activation upregulates antioxidant enzymes to counter this.

2. Dopamine Metabolism: Oxidation of dopamine generates reactive quinones and hydrogen peroxide. NRF2 activation enhances detoxification pathways.

3. Mitochondrial Dysfunction: Complex I deficiency in PD mitochondria produces excess ROS. NRF2 targets improve mitochondrial quality and function.

4. Neuroinflammation: Activated microglia in PD brain produce inflammatory cytokines and ROS. NRF2 inhibits NF-κB, reducing inflammatory activation.

5. Protein Aggregation: Alpha-synuclein fibrils can be generated or exacerbated by oxidative stress. NRF2-mediated reduction in oxidative stress may slow aggregation.

6. Blood-Brain Barrier Integrity: NRF2 activation in endothelial cells may help maintain BBB function in PD ^{6Sulforaphane NRF2 activation in neurodegenerative disease models2023 · Antioxidants · DOI 10.3390/antiox12081425Open reference}.

Competitive Position

SFX-01 occupies a unique position in the NRF2 activator landscape:

Key advantages of SFX-01:

• Potent, naturally occurring NRF2 activator with excellent brain penetration

• Proprietary stabilized formulation addresses historical instability issues

• Clinical data in PD patients demonstrating target engagement

• Favorable safety profile established across multiple trials

• Oral dosing for patient convenience and compliance

• Established GMP manufacturing ^{7SFX-01 clinical development and mechanism2022 · Neuropharmacology · PMID 35093365Open reference}

Corporate Information

Financial Overview

• Stock: LSE AIM, ticker EVG

• Market Cap: Approximately GBP 10-20M (as of 2024)

• Cash Position: Funded through ongoing clinical trials

• Investors: UK institutional and retail investors

Leadership

• Dr. Steve Jackson (CEO): Experienced biotech executive with background in CNS drug development and corporate strategy

• Management Team: Experienced pharmaceutical professionals with expertise in drug development, regulatory affairs, and commercial strategy

Partnerships

The company has explored strategic partnerships to advance SFX-01 development:

• Academic collaborations with leading PD research centers

• Clinical trial sites across Europe and the US

• Potential co-development or licensing discussions for specific indications

Cross-Links

• NRF2 Activators for Parkinson’s Disease

• NRF2 in Parkinson’s Disease

• Oxidative Stress in Parkinson’s Disease

• Parkinson’s Disease NRF2-KEAP1 Companies

• Alzheimer’s Disease NRF2-KEAP1 Companies

• NRF2 Protein

• NRF2 Gene

• Parkinson’s Disease

See Also

• Parkinson’s Disease

• Alzheimer’s Disease

• NRF2-KEAP1 Pathway

• Oxidative Stress in Neurodegeneration

• Broccoli and Neuroprotection

External Links

• Evgen Pharma Corporate Website

• LSE EVG Stock Information

• ClinicalTrials.gov